Ardalan Aminlari, MD
Glaucoma Specialist · Encinitas, CANPI 1639497258
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,732 of the $32,417 with a category attached, or 60.9%. 21 manufacturers reported payments, led by Glaukos Corporation at 58.1% of the total. 2025 is the largest year on record at $12,968, 3.2 times the $4,113 reported in 2019.
Across 278 payments — averaging $116.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$19K
- Alcon$4K
- Johnson & Johnson Surgical Vision, Inc.$2K
- NEW World Medical,inc.$2K
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- plus $3K from 15 others
Across 3 payments — averaging $5863.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$18K
What the payments were for
- Consulting fees$19,73261%
- Travel & lodging$660%
- Food & beverage$12,59539%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 31 | $18,820 |
| Alcon | 87 | $4,491 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $2,387 |
| NEW World Medical,inc. | 6 | $1,918 |
| Bausch & Lomb Americas Inc. | 29 | $1,189 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $1,021 |
| AbbVie(2 entities) | 34 | $646 |
| Kala Pharmaceuticals, Inc. | 12 | $477 |
| Novartis | 16 | $271 |
| Aerie Pharmaceuticals, Inc. | 9 | $258 |
| Rxsight Inc | 7 | $221 |
| Sight Sciences, Inc. | 4 | $205 |
| Tarsus Pharmaceuticals, Inc. | 5 | $154 |
| GSK | 1 | $118 |
| Oyster Point Pharma, Inc. | 3 | $68 |
| Amgen(2 entities) | 3 | $55 |
| Johnson & Johnson Vision Care, Inc. | 1 | $37 |
| Harrow Eye, LLC | 1 | $31 |
| Shire North American Group Inc | 1 | $19 |
| Thea Pharma Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$9,100
- iDose$4,442
- Tecnis Symfony IOL$2,132
- Ahmed Glaucoma Valve$1,773
- Kahook Dual Blade$1,773
- iAccess Precision Blade$1,500
- iDose Trio$1,500
- iDoseTR$1,295
- Clareon$823
- enVista MX60 IOL$772
- AcrySof$502
- ORA$375
- ACTIVEFOCUS$364
- iStent inject W$360
- ENVISTA$338
- LenSx$259
- Centurion$253
- INVELTYS$250
- ReSTOR$238
- iStent Infinite$165
How this compares
$32,417 in reported general payments places this provider in the 80th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 110 | $53,605 |
| RestasisCyclosporine | 20 | $24,702 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $18,101 |
| VyzultaLatanoprostene Bunod | 22 | $7,864 |
| Latanoprost | 558 | $6,634 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $6,485 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 32 | $6,458 |
| Alphagan PBrimonidine Tartrate | 12 | $6,263 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 258 | $5,650 |
| Brimonidine Tartrate | 67 | $5,130 |
| IyuzehLatanoprost/Pf | 15 | $4,447 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $3,261 |
| Travoprost | 16 | $3,077 |
| Timolol Maleate | 208 | $2,289 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $2,224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $646 | $91,055155 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $258 | $18,10128 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,189 | $7,86422 claims |
| Thea Pharma Inc.Iyuzeh | $19 | $4,44715 claims |
| AlconSimbrinza | $4,491 | $3,26116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Encinitas
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.